Skip to main content

Table 1 Baseline characteristics of the subjects

From: Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

 

Febuxostat

n = 105

Benzbromarone

n = 109

P value

Age, years

52.42 ± 11.73

50.27 ± 14.15

0.23

Onset age, years

41.80 ± 10.57

43.19 ± 13.15

0.48

Height, cm

172.65 ± 5.65

172.39 ± 5.83

0.77

Body weight, kg

78.89 ± 9.49

77.27 ± 9.55

0.28

BMI, kg/m2

26.59 ± 3.03

26.10 ± 2.75

0.25

Waistline, cm

94.60 ± 7.41

92.31 ± 7.92

0.10

Waist-to-hip ratio

0.92 ± 0.05

0.92 ± 0.04

0.65

Systolic BP, mmHg

128.42 ± 13.55

126.78 ± 16.93

0.51

Diastolic BP, mmHg

83.47 ± 8.74

82.07 ± 9.67

0.32

Coexisting conditions

 Hypertension

25 (22.9)

20 (19.0)

0.33

 Cardiovascular disease

5 (4.6)

7 (6.7)

0.60

 Diabetes

7 (6.4)

3 (2.9)

0.30

 Hyperlipidemia

32 (29.4)

34 (32.4)

0.91

 Fatty liver

26 (23.9)

28 (26.7)

0.88

 Tophus

26 (23.9)

21 (20)

0.33

 Family history of gout

24 (22.0)

26 (24.8)

0.86

  1. Data given as mean ± SD or number (%). *P ≤ 0.05. **P ≤ 0.01. BMI body mass index, BP blood pressure
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us